These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 504342)

  • 41. [Fluspirilene--safe weekly tranquilizer?].
    Kuhn W; Wöhrle M; Müller T; Welter F
    Nervenarzt; 1997 Jun; 68(6):528. PubMed ID: 9312689
    [No Abstract]   [Full Text] [Related]  

  • 42. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical symptomatology and drug compliance in schizophrenic patients.
    Bartkó G; Herczeg I; Zádor G
    Acta Psychiatr Scand; 1988 Jan; 77(1):74-6. PubMed ID: 2894746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
    Faltus F
    Act Nerv Super (Praha); 1974 Aug; 16(3):167-8. PubMed ID: 4607824
    [No Abstract]   [Full Text] [Related]  

  • 46. [New long-acting treatment of anxiety and its different forms of somatization: low-dose fluspirilene].
    Giannelli A; Zarattini F
    Minerva Med; 1983 Mar; 74(13):727-33. PubMed ID: 6835561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
    Woggon B; Bickel P; Schnyder B
    Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evaluation of fluspirilene as a maintenance therapy in chronic schizophrenic patients.
    Singh AN
    Can Psychiatr Assoc J; 1973 Oct; 18(5):415-9. PubMed ID: 4746145
    [No Abstract]   [Full Text] [Related]  

  • 49. Fluspirilene neuroleptic depot injections and indurations.
    McGee HM; Seeman MV; Deck JH
    Can J Psychiatry; 1983 Aug; 28(5):379-81. PubMed ID: 6627197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A factor analytic study of the action of some neuroleptics on chronic schizophrenic syndromes.
    Perris C; Hållberg B; Malm U; Wedrén G; Espvall M; Rapp W
    Acta Psychiatr Scand Suppl; 1974; 249():123-34. PubMed ID: 4607777
    [No Abstract]   [Full Text] [Related]  

  • 51. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis.
    Bankier RG
    J Clin Pharmacol New Drugs; 1973 Jan; 13(1):44-7. PubMed ID: 4566123
    [No Abstract]   [Full Text] [Related]  

  • 52. Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications.
    Knudsen P; Hansen LB; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():11-4. PubMed ID: 3865500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of schizophrenics with perphenazine enanthate].
    Madsen A; Sorensen J
    Nord Psykiatr Tidsskr; 1971; 25(5):475-8. PubMed ID: 5144306
    [No Abstract]   [Full Text] [Related]  

  • 54. Increase in weight after treatment with depot neuroleptics.
    Korsgaard S; Skausig OB
    Acta Psychiatr Scand; 1979 Feb; 59(2):139-44. PubMed ID: 420033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of depot tranquillisers in psychiatric disorders.
    Trimble M
    Br Med J; 1977 Dec; 2(6101):1541. PubMed ID: 589330
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-acting phenothiazines in alcoholism.
    Kinnell HG
    Lancet; 1977 Sep; 2(8039):659. PubMed ID: 71470
    [No Abstract]   [Full Text] [Related]  

  • 57. [Severe late-onset dystonia while on fluspirilene].
    Laux G; Gunreben G
    Dtsch Med Wochenschr; 1991 Jun; 116(25):977-80. PubMed ID: 2049986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The dose-effect relationship of 0.5, 1.0 and 1.5 mg fluspirilene on anxious patients.
    Lehmann E
    Neuropsychobiology; 1989; 21(4):197-204. PubMed ID: 2698453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Psychovegetative disorders in gynecology. Treatment with Imap 1.5 mg].
    Schwab H; Pein R; Wittenbeck K
    ZFA (Stuttgart); 1982 Dec; 58(35-36):1951-2. PubMed ID: 7164558
    [No Abstract]   [Full Text] [Related]  

  • 60. Ambulatory activity during treatment with fluspirilene in chronic schizophrenics.
    Perris C; Rapp W
    Acta Psychiatr Scand Suppl; 1974; 249():117-22. PubMed ID: 4608470
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.